Second Quarter 2021 Report
July 16, 2021
20/20 Makes List of Fastest Growing Private Companies in America
20/20 GeneSystems has made the Inc. 5000 list of the fastest-growing private companies in America! Companies on the 2021 Inc.5000 are ranked according to percentage revenue growth from 2017 to 2020. Being on the Inc.5000 means we are among the top 0.07% of U.S. companies in terms of growth. Companies founded by Mark Cuban, Rebecca Minkoff, Daymond John, and Bill Gates made this coveted list in prior years.

Inc. magazine will be issuing a major public release of this list on August 17 including each company's official rank on Inc.5000.
Semi-Annual Revenues Top $1.8 million; 19% Growth Over Same Period Last Year
For the 6 month period ending in June, 20/20's revenue exceeded $1,835,000 (unaudited) for all products compared to $1,545,634 during the first half of last year. Coronavirus associated testing accounted for about 85% of these revenues, largely as Montgomery County Maryland shifted testing to our lab because of satisfaction with our performance.

Cancer test revenue during this period was $155,426 compared to $90,505 during the first half of 2020. We anticipate accelerated growth of cancer testing in 2H'21. 20/20 is actively seeking new tests to add to our portfolio to replace the inevitable decline in Covid-19 testing. We believe that our CLIAx accelerator will contribute significantly towards that goal (see below).
Trading of 20/20 Stock to Commence Next Month
20/20 has agreed to list our shares on StartEngine Secondary giving interested shareholders an opportunity to trade their shares. Trading is expected to commence in August.

This new alternative trading system (ATS) is regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. Listing on StartEngine Secondary will permit our shareholders to buy or sell 20/20 stock with certain restrictions. Please be on the lookout for an announcement in August that we are live on StartEngine Secondary. You can also visit www.startengine.com/trade.

An informational webinar for shareholders will be held next month shortly after we commence trading on StartEngine Secondary.

Please Note: 20/20 reserves the right to forgo listing on the ATS due to (a) changes in its commercial trajectory as a result of, without limitation, its own commercial progress, that of its competitors, or changes to regulatory or economic conditions, (b) the performance of the ATS with regard to other issuers, or (c) an imminent listing on a national stock exchange such as NASDAQ. Investors should not invest in this Offering with the expectation that near term liquidity through StartEngine Secondary or other means will be available.

You should read the Offering Circular and Risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA/SPIC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.


 
20/20's Clinical Lab Innovation Accelerator Designated a "Soft Landing" Site by Maryland Commerce Department
In the fall we will begin our shared clinical laboratory operations, with space for start-ups and international companies seeking to introduce their novel lab tests to the U.S. market. "The Clinical Lab Innovation Axcellerator (CLIAx)" is believed to be the first shared lab facility providing access to testing equipment and personnel that comply with federal and state regulations under the Clinical Laboratory Improvement Amendments (CLIA). Setting up, staffing, and maintaining a compliant CLIA lab can be daunting for young companies as it involves facility leasing, hiring qualified laboratory personnel, purchasing analyzers and other testing equipment.  
 
A CLIAx promotional video may be viewed here and the brochure may be downloaded here. 
 
The Maryland Department of Commerce has officially designated our Accelerator as one of their "Soft Landing" programs for overseas companies. The Soft Landing program is promoted on this website along with a blog post, and press release. Technical.ly also ran a story about the Maryland program.
 
20/20 is targeting companies with tests that address a similar or complementary market to our OneTest, namely early detection and wellness, and is seeking U.S. marketing rights to these tests. Thus, in addition to effectively managing our overhead expenses CLIAx is expected to be a platform to permit 20/20 to grow its product pipeline while maintaining low to nominal R&D expenditures and risks.
 
Negotiations are currently underway with several companies interested in CLIAx.

Our previous Quarterly Reports and Press Releases may be downloaded here:
Financial Reports
In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at https://www.sec.gov/edgar/searchedgar/companysearch.html or by contacting investors@2020gene.com
Regulation A Offering and Forward Looking Statements
20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: https://www.sec.gov/edgar/searchedgar/companysearch.html
A QUALIFIED OFFERING ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.